Extrahepatic cancer suppresses nuclear receptor-regulated drug metabolism

Clinical Cancer Research

Volumn 17, Issue 10, 2011, Pages 3170-3180

  Kacevska, Marina ^a   Downes, Michael R ^b   Sharma, Rohini ^a   Evans, Ronald M ^b   Clarke, Stephen J ^a   Liddle, Christopher ^a   Robertson, Graham R ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ALBUMIN D SITE BINDING PROTEIN; BINDING PROTEIN; CARNITINE PALMITOYLTRANSFERASE I; CARNITINE PALMITOYLTRANSFERASE I ALPHA; CCAAT ENHANCER BINDING PROTEIN ALPHA; CCAAT ENHANCER BINDING PROTEIN BETA; CD36 ANTIGEN; CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450 2B; CYTOCHROME P450 2B10; CYTOCHROME P450 3A; CYTOCHROME P450 3A11; CYTOCHROME P450 4A; CYTOCHROME P450 4A14; ERR ALPHA ORPHAN RECEPTOR; ERR BETA ORPHAN RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 3GAMMA; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; LIVER X RECEPTOR; NUCLEAR RECEPTOR NR1D1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PREGNANE X RECEPTOR; RECEPTOR PROTEIN; RETINOID X RECEPTOR ALPHA; SHP ORPHAN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIMERIZATION; GENE EXPRESSION PROFILING; GENE INDUCTION; GENE REPRESSION; LIVER; LIVER CELL; LIVER METABOLISM; MALE; MOUSE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REPORTER GENE; SARCOMA; TRANSGENIC MOUSE;

ANIMALS; CELL LINE, TUMOR; CYTOCHROME P-450 CYP3A; DOWN-REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; LAC OPERON; LIVER; MALE; METABOLIC DETOXICATION, DRUG; MICE; MICE, TRANSGENIC; NEOPLASMS; PHARMACEUTICAL PREPARATIONS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SARCOMA, EXPERIMENTAL;

EID: 79956022970     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-3289     Document Type: Article

References (46)

1. Rivory LP, Slaviero KA, Clarke SJ. Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. Br J Cancer 2002;87:277-80.
2. Slaviero KA, Clarke SJ, McLachlan AJ, Blair EY, Rivory LP. Population pharmacokinetics of weekly docetaxel in patients with advanced cancer. Br J Clin Pharmacol 2004;57:44-53. (Pubitemid 38067949)
3. Sharma R, Cunningham D, Smith P, Robertson G, Dent O, Clarke SJ. Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients-analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO. BMC Cancer 2009;9:153.
4. Slaviero KA, Clarke SJ, Rivory LP. Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol 2003;4:224-32. (Pubitemid 36503320)
5. Kacevska M, Robertson GR, Clarke SJ, Liddle C. Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing. Expert Opin Drug Metab Toxicol 2008;4:137-49. (Pubitemid 351308413)
6. Brian WR, Sari MA, Iwasaki M, Shimada T, Kaminsky LS, Guengerich FP. Catalytic activities of human liver cytochrome P-450 IIIA4 expressed in Saccharomyces cerevisiae. Biochemistry 1990;29: 11280-92.
7. Stedman C, Robertson G, Coulter S, Liddle C. Feed-forward regulation of bile acid detoxification by CYP3A4: studies in humanized transgenic mice. J Biol Chem 2004;279:11336-43. (Pubitemid 38401631)
8. Charles KA, Rivory LP, Brown SL, Liddle C, Clarke SJ, Robertson GR. Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer. Clin Cancer Res 2006;12:7492-7. (Pubitemid 46095425)
9. Sharma R, Kacevska M, London R, Clarke SJ, Liddle C, Robertson G. Downregulation of drug transport and metabolism in mice bearing extra-hepatic malignancies. Br J Cancer 2008;98:91-7.
10. Skipworth RJ, Stewart GD, Dejong CH, Preston T, Fearon KC. Pathophysiology of cancer cachexia: much more than host-tumour interaction? Clin Nutr 2007;26:667-76.
11. Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980;69: 491-7. (Pubitemid 10018703)
12. Bruera E.ABC of palliative care. Anorexia, cachexia, and nutrition. BMJ 1997;315:1219-22.
13. Fearon KC. Cancer cachexia: developing multimodal therapy for a multidimensional problem. Eur J Cancer 2008;44:1124-32.
14. Stephens NA, Skipworth RJ, Fearon KC. Cachexia, survival and the acute phase response. Curr Opin Support Palliat Care 2008;2:267-74.
15. Maglich JM, Sluder A, Guan X, Shi Y, McKee DD, Carrick K, et al. Comparison of complete nuclear receptor sets from the human, Caenorhabditis elegans and Drosophila genomes. Genome Biol 2001;2:RESEARCH0029.
16. Sonoda J, Pei L, Evans RM. Nuclear receptors: decoding metabolic disease. FEBS Lett 2008;582:2-9. (Pubitemid 350297241)
17. Evans RM. The nuclear receptor superfamily: a rosetta stone for physiology. Mol Endocrinol 2005;19:1429-38. (Pubitemid 41002974)
18. Karpen SJ. Nuclear receptor regulation of hepatic function. J Hepatol 2002;36:832-50. (Pubitemid 35177416)
19. Francis GA, Fayard E, Picard F, Auwerx J. Nuclear receptors and the control of metabolism. Ann Rev Physiol 2003;65:261-311. (Pubitemid 38249155)
20. Ip E, Farrell GC, Robertson G, Hall P, Kirsch R, Leclercq I. Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology 2003;38:123-32. (Pubitemid 36775803)
21. Robertson GR, Field J, Goodwin B, Bierach S, Tran M, Lehnert A, et al. Transgenic mouse models of human CYP3A4 gene regulation. Mol Pharmacol 2003;64:42-50. (Pubitemid 36759816)
22. Li X, Hansen PA, Xi L, Chandraratna RA, Burant CF. Distinct mechanisms of glucose lowering by specific agonists for peroxisomal proliferator activated receptor gamma and retinoic acid X receptors. J Biol Chem 2005;280:38317-27. (Pubitemid 43860306)
23. Sigrist S, Bedoucha M, Boelsterli UA. Down-regulation by troglitazone of hepatic tumor necrosis factor-alpha and interleukin-6 mRNA expression in a murine model of non-insulin-dependent diabetes. Biochem Pharmacol 2000;60:67-75. (Pubitemid 30243086)
24. Compe E, Drane P, Laurent C, Diderich K, Braun C, Hoeijmakers JH, et al. Dysregulation of the peroxisome proliferator-activated receptor target genes by XPD mutations. Mol Cell Biol 2005;25:6065-76. (Pubitemid 40946558)
25. Swarm RL. Transplantation of a murine chondrosarcoma in mice of different inbred strains. J Natl Cancer Instit 1963;31:953-75.
26. Futaki S, Hayashi Y, Yamashita M, Yagi K, Bono H, Hayashizaki Y, et al. Molecular basis of constitutive production of basement membrane components. Gene expression profiles of Engelbreth-Holm-Swarm tumor and F9 embryonal carcinoma cells. J Biol Chem 2003;278:50691-701. (Pubitemid 37548918)
27. Martinez-Jimenez CP, Jover R, Donato MT, Castell JV, Gomez-Lechon MJ. Transcriptional regulation and expression of CYP3A4 in hepatocytes. Curr Drug Metab 2007;8:185-94. (Pubitemid 46218685)
28. Jover R, Bort R, Gomez-Lechon MJ, Castell JV. Down-regulation of human CYP3A4 by the inflammatory signal interleukin-6: molecular mechanism and transcription factors involved. FASEB J 2002; 16:1799-801.
29. Ghose R, Zimmerman TL, Thevananther S, Karpen SJ. Endotoxin leads to rapid subcellular re-localization of hepatic RXRalpha: a novel mechanism for reduced hepatic gene expression in inflammation. Nucl Recept 2004;2:4.
30. Zimmerman TL, Thevananther S, Ghose R, Burns AR, Karpen SJ. Nuclear export of retinoid X receptor alpha in response to interleukin-1beta-mediated cell signaling: roles for JNK and SER260. J Biol Chem 2006;281:15434-40. (Pubitemid 43855135)
31. Ruminy P, Gangneux C, Claeyssens S, Scotte M, Daveau M, Salier JP. Gene transcription in hepatocytes during the acute phase of a systemic inflammation: from transcription factors to target genes. Inflamm Res 2001;50:383-90. (Pubitemid 32777664)
32. Beigneux AP, Moser AH, Shigenaga JK, Grunfeld C, Feingold KR. Reduction in cytochrome P-450 enzyme expression is associated with repression of CAR (constitutive androstane receptor) and PXR (pregnane X receptor) in mouse liver during the acute phase response. Biochem Biophy Res Commun 2002;293:145-9. (Pubitemid 34694183)
33. Pascussi JM, Gerbal-Chaloin S, Pichard-Garcia L, Daujat M, Fabre JM, Maurel P, et al. Interleukin-6 negatively regulates the expression of pregnane X receptor and constitutively activated receptor in primary human hepatocytes. Biochem Biophys Res Commun 2000; 274:707-13. (Pubitemid 30663683)
34. Morgan ET. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin Pharmacol Ther 2009;85:434-8.
35. Renton KW. Regulation of drug metabolism and disposition during inflammation and infection. Expert Opin Drug Metab Toxicol 2005;1:629-40.
36. Goodwin B, Hodgson E, Liddle C. The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol Pharmacol 1999;56: 1329-39.
37. Maglich JM, Lobe DC, Moore JT. The nuclear receptor CAR (NR1I3) regulates serum triglyceride levels under conditions of metabolic stress. J Lipid Res 2009;50:439-45.
38. Ghose R, Mulder J, von Furstenberg RJ, Thevananther S, Kuipers F, Karpen SJ. Rosiglitazone attenuates suppression of RXRalpha-dependent gene expression in inflamed liver. J Hepatol 2007;46:115-23. (Pubitemid 44827424)
39. Gombart AF, Luong QT, Koeffler HP. Vitamin D compounds: activity against microbes and cancer. Anticancer Res 2006;26:2531-42. (Pubitemid 44155532)
40. Poon MM, Chen L. Retinoic acid-gated sequence-specific translational control by RARalpha. Proc Natl Acad Sci U S A 2008; 105:20303-8.
41. Szafran AT, Szwarc M, Marcelli M, Mancini MA. Androgen receptor functional analyses by high throughput imaging: determination of ligand, cell cycle, and mutation-specific effects. PLoS ONE 2008;3: e3605.
42. Vlaeminck-Guillem V, Wemeau JL. Physiology and pathophysiology of thyroid hormone receptors: the contributions of murine models. Ann Endocrinol (Paris) 2000;61:440-51.
43. Burris TP. Nuclear hormone receptors for heme: REV-ERBalpha and REV-ERBbeta are ligand-regulated components of the mammalian clock. Mol Endocrinol 2008;22:1509-20. (Pubitemid 351920387)
44. Heyman RA, Mangelsdorf DJ, Dyck JA, Stein RB, Eichele G, Evans RM, et al. 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor. Cell 1992;68:397-406.
45. Altucci L, Leibowitz MD, Ogilvie KM, de Lera AR, Gronemeyer H. RAR and RXR modulation in cancer and metabolic disease. Nat Rev Drug Discov 2007;6:793-810. (Pubitemid 47504871)
46. Takamatsu K, Takano A, Yakushiji N, Morohashi K, Morishita K, Matsuura N, et al. The first potent subtype-selective retinoid X receptor (RXR) agonist possessing a 3-isopropoxy-4-isopropylphenylamino moiety, NEt-3IP (RXRalpha/beta-dual agonist). Chem Med Chem 2008;3:780-7.